Celcuity, Inc. (NASDAQ:CELC) Given Average Recommendation of “Moderate Buy” by Analysts

Celcuity, Inc. (NASDAQ:CELC) has earned an average rating of “Moderate Buy” from the ten brokerages that are presently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have issued a buy rating and one has issued a strong buy rating on the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $105.25.

Several equities research analysts recently issued reports on the stock. Jefferies Financial Group lifted their price target on shares of Celcuity from $108.00 to $134.00 and gave the stock a “buy” rating in a research note on Tuesday, December 2nd. HC Wainwright reaffirmed a “neutral” rating and set a $94.00 target price (up from $77.00) on shares of Celcuity in a research report on Monday, November 17th. Stifel Nicolaus boosted their price target on Celcuity from $68.00 to $115.00 and gave the stock a “buy” rating in a research note on Thursday, November 13th. Wells Fargo & Company assumed coverage on Celcuity in a research note on Friday, December 12th. They set an “overweight” rating and a $126.00 price objective for the company. Finally, Craig Hallum lifted their price objective on Celcuity from $96.00 to $108.00 and gave the stock a “buy” rating in a report on Thursday, November 13th.

Insider Activity

In related news, Director Richard E. Buller sold 3,000 shares of the company’s stock in a transaction on Friday, December 5th. The shares were sold at an average price of $105.69, for a total value of $317,070.00. Following the sale, the director directly owned 6,760 shares of the company’s stock, valued at $714,464.40. This represents a 30.74% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 15.77% of the company’s stock.

Institutional Investors Weigh In On Celcuity

Institutional investors have recently modified their holdings of the stock. Nisa Investment Advisors LLC raised its holdings in shares of Celcuity by 2,142.0% during the third quarter. Nisa Investment Advisors LLC now owns 15,627 shares of the company’s stock worth $772,000 after purchasing an additional 14,930 shares during the period. Saturn V Capital Management LP grew its position in shares of Celcuity by 8.4% during the 2nd quarter. Saturn V Capital Management LP now owns 1,185,520 shares of the company’s stock valued at $15,827,000 after buying an additional 91,843 shares during the last quarter. M Holdings Securities Inc. bought a new stake in shares of Celcuity during the 2nd quarter valued at about $224,000. Corton Capital Inc. acquired a new stake in Celcuity during the second quarter worth about $175,000. Finally, Harbor Capital Advisors Inc. acquired a new stake in Celcuity during the third quarter worth about $399,000. Institutional investors and hedge funds own 63.33% of the company’s stock.

Celcuity Trading Down 0.6%

NASDAQ CELC opened at $110.13 on Friday. The company has a market cap of $5.10 billion, a P/E ratio of -30.01 and a beta of 0.25. Celcuity has a 12 month low of $7.57 and a 12 month high of $116.44. The company has a debt-to-equity ratio of 2.74, a current ratio of 12.26 and a quick ratio of 12.26. The company has a 50-day moving average of $102.29 and a 200-day moving average of $68.65.

Celcuity (NASDAQ:CELC) last issued its earnings results on Wednesday, November 12th. The company reported ($0.92) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.05) by $0.13. As a group, equities analysts predict that Celcuity will post -2.62 earnings per share for the current year.

About Celcuity

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.